Literature DB >> 30022909

Giant-cell tumors of soft tissue in the head and neck: A review article.

Shahd M Hafiz1, Eman S Bablghaith1, Amal J Alsaedi1, Mohammad H Shaheen1.   

Abstract

Giant-cell tumor of soft tissue (GCT-ST) is a rare neoplasm that was first described in 1972. Due to its histological and immune-histochemical similarities with GCT of bones, GCT-ST is thought to be its counterpart. This review article aims to recognize the characteristics of this rare tumor along with a favorable way to diagnose and treat. We reviewed 12 cases of GCT-ST in the head and neck. This tumor involves both sexes at any age. Histopathology in many cases revealed the presence of mononuclear cells and spindle cells. Immunohistochemistry was positive in many cases for CD68. Complete excision was the most accepted management technique; however, few cases reported recurrence and metastasis. Post-operative radiology is suggested to prevent local recurrence and in case of incomplete excision of the tumor.

Entities:  

Keywords:  Giant-cell; head and neck; review; tumor

Year:  2018        PMID: 30022909      PMCID: PMC6040846     

Source DB:  PubMed          Journal:  Int J Health Sci (Qassim)        ISSN: 1658-3639


Introduction

Giant-cell tumor of soft tissue (GCT-ST) is a rare neoplasm that was first described in 1972.[1,2] Due to its histological and immunohistochemical similarities with GCT of bones, GCT-ST is thought to be its counterpart.[3] The World Health Organization classifies the tumor as a GCT-ST with low malignant potential (GCT-LMP) and malignant GCT-ST.[4-6] GCT-ST is characterized by the presence of spindles or polygonal mononuclear cells and multinucleated osteoclast-like giant cells.[2] Atypia and necrosis are present in the malignant form of GCT-ST. GCT-LMP is most commonly found in superficial soft tissue of upper and lower extremities, especially on hands, arms, and feet.[1,4,7-13] The head and neck region is rarely affected.[3] In most patients, the chief complaint is a painless well-circumscribed mass covered by normal skin or by a fleshy red-brown surface when superficially located.[2,13,14] The duration of the mass varies between 2 and 12 months.[2] There is no predominant age group affected by the tumor specifically, as it occurs in a broad age range from 5 to 84 years with no sex predilection.[1,4,7-12,15] No exact etiological factors have been identified.[6] Differential diagnosis should include benign lesions (such as GCT of tendon sheaths, cellular dermatofibroma with osteoclast-like giant cells, ossifying dermatofibroma with osteoclast-like giant cells, reparative giant-cell granuloma, nodular fasciitis, and brown tumor of hyperparathyroidism extending to soft tissues) and malignant lesions (leiomyosarcoma with osteoclast-like giant cells, epithelioid sarcoma with giant cells, extraskeletal osteosarcoma, atypical fibroxanthoma with osteoclast-like giant cells, and plexiform fibrohistiocytic tumor).[2,16-18] Cytopathology, histopathology, and immunostains for smooth muscle actin and CD68 are important for confirming the diagnosis and ruling out neoplastic and non-neoplastic differential diagnoses.[3] Complete excision with a free surgical margin is thought to be the best treatment approach.[3,9,15,19] There have been a few reported cases of local recurrence and metastasis with positive surgical margins.[20] As GCT-ST is radiosensitive,[1,21] radiotherapy should be considered for cases with incomplete surgical margin excision due to its proximity to critical structures.[15,16] This tumor has biologically benign behavior,[17,18] and thus, removal of the tumor with clear surgical margins guarantees no recurrence.[22] However, strict follow-up is recommended, as local recurrence and metastasis cannot be predicted.[13,14] This review article aimed to recognize the characteristics of this rare tumor along with favorable ways to diagnose and treat it.

Results and Discussion

Literature reviews of GCT-ST cases were identified between 1981 and 2016 using the search engines PubMed, Ovid, and Medline. The keywords were as follows: GCT-ST and GCT-LMP. We included all cases of GCT-ST in the head and neck region. The language was limited to English, and we excluded GCT of bones, cartilages, other body regions, and glands. We reviewed 12 cases, as described in Table 1. All cases are arranged chronologically from 1981 to 2016. We searched for study type, year of publication, patient demographics, initial presentation, and the tumor site. We focused on the tumor features by discussing the physical examination findings and radiological test reports if applicable, while all microscopic examinations data were collected. Additional tests included immunohistochemical staining, in addition to management plans and follow-up outcomes.
Table 1

GCT cases

GCT cases Most patients, 7 of them, were male (58.3%)[3,9,10,20,23-25] and 5 (41.7%)[13,15,26-28] were female. This tumor involves a wide age range from 9 to 75 years, but more commonly affects middle-aged individuals. For the site, 7 (58.3%) cases involved multiple sites in the head: Forehead, temporal area, parotid, ear, nose, superior, and inferior lip.[13,15,20,23,25-28] In the neck region, however, 5 (41.7%) cases were located in different neck triangles.[3,9,10,24,27] The main complaint was a painless growing mass in 9 (75%) cases.[3,9,10,13,15,20,23,24,27] However, 3 (25%) cases reported different complaints based on the site of the tumor including sinus infection, otorrhea, loss of vision, and headache.[25,26,28] Most cases described the mass as slow-growing, well-circumscribed, and covered by normal skin, while only 1 case had pus and discharge, and another case had an exophytic mass.[23,28] The mass sizes ranged between 15 mm and 5 cm. The duration of symptoms was between 1 month and 1 year. For radiological examination, computed tomography scan showed no relation to the bone. Microscopic examination revealed most of the tumors were composed of osteoclast-like multinucleated giant cells, mononuclear cells, and spindle cells in 6 (50%) cases. In almost a third of the cases, 4 subjects (33.3%) exhibited a mild to moderate degree of nuclear atypia and nuclear pleomorphism,[10,13,26,28] which are indicators of malignancy. The osteoclast-like giant cells showed strongly positive CD68 in 9 (75%) cases[3,13,15,20,23-27] and were negative for CD34 in 3 (25%) cases.[13,15,20] Surgical excision, which is the most accepted management technique, was done for all cases except for one that was managed by subtotal resection.[25] All cases were followed up except for 2 cases.[9,23] Metastasis to the lung was reported in 1 case, and the patient died 1 year later.[10] Recurrence rate was very low; specifically, 1 case had recurrence after 6 months of resection in the tibia.[13] Post-operative radiotherapy was given for 2 (16.7%) cases, one of which reported that the period of its course was over 5 weeks with no evidence of recurrence and metastasis.[15,27] There are no definitive studies supporting post-operative radiotherapy; however, it is suggested because of the possibility of recurrence, especially for cases with incomplete excision.

Conclusion

We reviewed 12 cases of GCT-ST in the head and neck. This tumor involves both sexes at any age. Histopathology in many cases revealed the presence of mononuclear cells and spindle cells. Immunohistochemistry was also positive in many cases for CD68. Complete excision was the most accepted management. However, few cases reported recurrence and metastasis. Post-operative radiology is suggested to prevent local recurrence and in case of incomplete excision of the tumor.
  24 in total

1.  Primary giant cell tumor of soft tissues: a study of 22 cases.

Authors:  A M Oliveira; A P Dei Tos; C D Fletcher; A G Nascimento
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

2.  Giant-cell tumours of soft tissues.

Authors:  R Salm; H A Sissons
Journal:  J Pathol       Date:  1972-05       Impact factor: 7.996

3.  Malignant giant cell tumor of soft parts. An analysis of 32 cases.

Authors:  J G Guccion; F M Enzinger
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

4.  Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts.

Authors:  A L Folpe; R J Morris; S W Weiss
Journal:  Mod Pathol       Date:  1999-09       Impact factor: 7.842

5.  A case of giant cell tumor of the parotid gland.

Authors:  Y Itoh; Y Taniguti; K Arai
Journal:  Ann Plast Surg       Date:  1992-02       Impact factor: 1.539

6.  Giant cell tumor of the skin: a morphologic and immunohistochemical study of five cases.

Authors:  Mai P Hoang; Beverly B Rogers; Jorge Albores-Saavedra
Journal:  Ann Diagn Pathol       Date:  2002-10       Impact factor: 2.090

7.  Primary giant cell tumor of soft tissue of the groin - a case of 46 years duration.

Authors:  Vinicio Boneschi; Antonina Parafioriti; Elisabetta Armiraglio; Francesca Gaiani; Lucia Brambilla
Journal:  J Cutan Pathol       Date:  2009-02-04       Impact factor: 1.587

8.  Giant Cell Tumour of Soft Tissue in Neck: An Uncommon Tumour in an Uncommon Location.

Authors:  Abhishek Bandyopadhyay; Binny Khandakar; Sripurna Medda; Soumit Dey; Prabir Chandra Paul
Journal:  J Clin Diagn Res       Date:  2015-12-01

9.  Malignant giant cell tumor of soft tissues: a clinicopathologic, cytologic, ultrastructural, angiographic, and microangiographic study.

Authors:  L Angervall; B Hagmar; L G Kindblom; C Merck
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

10.  Giant cell tumor of soft tissue of neck: a case report.

Authors:  Amel Trabelsi; Faten Hammedi; Abdelfateh Slama; Soumaya Ben Abdelkarim; Nadia Beïzig; Habib Khochtali; Yacoubi Mohamed Taher; Sadok Korbi
Journal:  N Am J Med Sci       Date:  2009-11
View more
  1 in total

1.  Efficacy of Pazopanib in the Treatment of Metastatic Malignant Giant Cell Tumor of Soft Tissue: A Case Report.

Authors:  Tadashi Iwai; Naoto Oebisu; Manabu Hoshi; Naoki Takada; Hiroaki Nakamura
Journal:  Curr Oncol       Date:  2022-01-31       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.